Exicure, Inc. (XCUR)
NASDAQ: XCUR · IEX Real-Time Price · USD
0.310
-0.023 (-6.79%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Exicure Revenue
Exicure had revenue of $500.00K in the twelve months ending March 31, 2024, down -98.10% year-over-year. Revenue in the quarter ending March 31, 2024 was $500.00K.
Revenue (ttm)
$500.00K
Revenue Growth
-98.10%
P/S Ratio
5.37
Revenue / Employee
$100,000
Employees
5
Market Cap
2.68M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 28.83M | 29.31M | -6,068.12% |
Dec 31, 2021 | -483.00K | -17.10M | -102.91% |
Dec 31, 2020 | 16.61M | 15.32M | 1,181.87% |
Dec 31, 2019 | 1.30M | 1.18M | 998.31% |
Dec 31, 2018 | 118.00K | -9.60M | -98.79% |
Dec 31, 2017 | 9.72M | 8.68M | 838.13% |
Dec 31, 2016 | 1.04M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Healthcare Triangle | 27.47M |
Tenon Medical | 3.21M |
Sintx Technologies | 2.78M |
Helius Medical Technologies | 668.00K |
Catheter Precision | 439.00K |
Sonnet BioTherapeutics Holdings | 92.73K |
XCUR News
- 15 days ago - Exicure, Inc. Reports First Quarter 2024 Financial Results - Business Wire
- 26 days ago - Exicure, Inc. Reports Full Year 2023 Financial Results - Business Wire
- 5 weeks ago - Exicure, Inc. Received Nasdaq Notice of a Delisting Determination - Business Wire
- 6 weeks ago - Exicure, Inc. Reports Third Quarter 2023 Financial Results - Business Wire
- 2 months ago - Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K - Business Wire
- 5 months ago - Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis - Business Wire
- 7 months ago - Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - Business Wire
- 11 months ago - Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors - Business Wire